Healix Infusion Therapy and Collaborators Publish Real-World Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study

SUGAR LAND, TX – (March 20, 2020)

Healix Infusion Therapy, LLC, announced today the publication of a collaborative study in the
leading scientific journal, Open Forum Infectious Diseases. This real-world multicenter study
demonstrated successful prevention of recurrence of Clostridioides difficile infection (CDI) with
bezlotoxumab use in U.S. infusion centers, which was comparable to clinical trial results despite
the presence of a more comorbid, higher at-risk patient population with an extensive history of

The Healix team collaborated with researchers from Atlanta ID Group, GI Alliance, Mazur,
Statner, Dutta, Nathan, PC, University of Houston College of Pharmacy, and Merck & Co., Inc.
The group retrospectively evaluated 200 patients who received a single dose of bezlotoxumab in
34 outpatient infusion centers.

“This is the largest study, and first in the United States, to show real-world evidence of
bezlotoxumab for prevention of Clostridioides difficile infection,” commented Lucinda Van
Anglen, PharmD, Vice President of Clinical Pharmacy & Research at Healix. “Our findings
showed an 84.1% success rate in preventing recurrences in a high-risk group. An outpatient
infusion center provides an optimal setting to treat these patients.”

The primary author of the study, Richard L. Hengel, MD, with Atlanta ID Group, added,
“Bezlotoxumab was shown to be safe and effective as a single 60-minute infusion. We had a
better than expected outcome in patients with at least one CDI risk factor versus those reported in clinical trials.” Hengel continued, “Our data indicate that use of bezlotoxumab earlier in the disease course was beneficial, and we are hopeful that physicians may consider bezlotoxumab
early in treatment of recurrent Clostridioides difficile infection, even prior to fecal microbiota transplant.”

About Healix Infusion Therapy, LLC
Healix is the nation’s leader in providing physician office-based infusion services. Focused on
patient and physician peace of mind for 30 years, we offer unparalleled capabilities for optimal
patient care, comfort, compliance, and clinical outcomes in an outpatient setting.

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.